Benzinga | Feb 2, 2021 08:15AM EST

Barclays Upgrades Dr Reddy's Laboratories to Overweight, Raises Price Target to $70

Barclays analyst Balaji Prasad upgrades Dr Reddy's Laboratories (NYSE:RDY) from Equal-Weight to Overweight and raises the price target from $56 to $70.